Chemicals maker DuPont
The outlook comes as the chemical industry struggles to recover from a recession that sharply curtailed demand. Many of DuPont's customers, including automakers and electronics manufacturers, cut their spending during the past year.
As a consequence, DuPont aggressively slashed costs and realigned its business earlier this year to try to rebound quicker.
DuPont is meeting the economic recovery as a stronger, faster and more agile global competitor, Chief Executive Ellen Kullman said at the company's annual investor day, her first as CEO. We are well positioned to outperform the rate at which markets recover and improve.
For the 2010 fiscal year, DuPont expects earnings of $2.10 to $2.40 per share excluding one-time items.
By that measure, analysts expect $2.24 per share, according to Thomson Reuters I/B/E/S estimates.
The company forecast sales for the year of $29 billion, higher than analysts' forecast of $28.12 billion.
Chief Financial Officer Nick Fanandakis, also in his first meeting in an executive role, told attendees, The recovery is really starting now.
The bullish outlook comes despite the 2010 loss of patent protection for the blood pressure drugs Cozaar and Hyzaar.
The drugs are expected to add $1.1 billion to DuPont's pre-tax earnings this year. That is expected to drop to between $300 million and $350 million next year, and to $70 million in 2012.
We will deliver earnings growth next year despite the Cozaar earnings growth decline, Kullman told investors.
The company expects earnings per share to grow at a compound annual rate of 20 percent over the next three years.
Emerging markets are expected to help fuel much of that growth, the Wilmington, Delaware-based based company said.
Over the next three years, revenue from emerging markets -- countries like India and China, among others -- is expected to jump 50 percent to $12 billion.
To help fuel that growth, the company has slashed staff in developed area like the United States and Europe, and boosted staffing in Latin America, Asia/Pacific and Eastern Europe.
DuPont shares rose 31 cents to $32.58 in morning trading on the New York Stock Exchange.
(Reporting by Ernest Scheyder, editing by Maureen Bavdek and John Wallace)